T1	p 92 114	stable COPD patients .
T2	p 129 144	COPD patients ,
T3	p 589 763	days , 60 COPD patients underwent dyspnea evaluation ( VAS score ) and pulmonary function testing at baseline and one hour after placebo or 300?g indacaterol administration .
T4	p 842 853	45 patients
T5	i 556 571	bronchodilators
T6	i 718 725	placebo
T7	i 735 746	indacaterol
T8	i 1352 1367	bronchodilators
T9	i 1370 1381	?sRAW-based
T10	o 26 40	bronchodilator
T11	o 70 80	resistance
T12	o 209 226	expiratory volume
T13	o 260 268	capacity
T14	o 317 323	muscle
T15	o 363 385	dynamic hyperinflation
T16	o 388 400	gas trapping
T17	o 403 423	and possibly dyspnea
T18	o 623 686	dyspnea evaluation ( VAS score ) and pulmonary function testing
T19	o 901 938	of intrathoracic gas volume ( ?ITGV )
T20	o 964 987	residual volume ( ?RV )
T21	o 1169 1207	of ?ITGV ( p=0.002 ) , ?RV ( p=0.023 )
T22	o 1210 1218	and ?VAS
T23	o 1523 1530	dyspnea